Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.
Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.
Now available on demand! Explore the applications for small molecule biomarkers in cell & gene therapy development.
“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached me with a fascinating problem. He had access to a biobank of human samples that, with current technology, would take the better part of a decade to analyze and wanted to know if I could… Continue reading The Future Is Now: Authority Magazine Interview with Sapient’s Jeramie Watrous
At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. Biomarkers allow us to better align the right patient with the right disease biology and ultimately the right therapy – and this alignment is what allows for more efficient and successful development. That is why we have developed… Continue reading Sapient Fact Sheet
“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated into one definition that all result in the same end pathology. Whether that end pathology is heart disease, Alzheimer’s disease, liver disease, lung disease, GI illness, renal disease, et cetera. Now, we know it to… Continue reading Futurati Podcast: Biomarkers and personalized medicine
The inherent heterogeneity in patient populations can often lead to variable drug response. We recently worked with a client who came to us after their Phase III clinical trial for a rare disease indication, consisting of several hundred participants, failed to reach its primary endpoint. We asked, can we identify a biomarker that indicates patients… Continue reading Discovery of a PD Biomarker to Predict Drug Response
Did you know that underlying risks for most common human diseases are not encoded in DNA sequence? Rather, they are revealed in circulating chemistry stemming from human exposures including diet, toxicants, internal organs, medications, and the environment. Learn how Sapient’s transformative platform can be used for untargeted biomarker discovery and profiling, probing deep into the… Continue reading Circulating Biomarker Discovery at Unprecedented Speed & Scale
There are tens of thousands of unmapped molecules circulating in human blood – thousands of which could represent robust biomarkers. Technologies to date have simply been too slow to map them efficiently. Sapient’s nontargeted metabolomics lab and methods – powered by next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) and a robust follow-on technology pipeline – are… Continue reading Fact Sheet: Analytical Methods from Discovery to Diagnostic Development
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical… Continue reading Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)
The PD-1 pathway has transformed the development of immunotherapies as a means to reawaken the immune system to target cancer cells. Clinically, however, there is a great deal of heterogeneity in the response to PD-1 based therapeutics across cancer patients, irrespective of the underlying tumor. There is some data to suggest that tumor burden mutational… Continue reading Discovery of PD-1 Pathway Biomarkers of Target Engagement
10421 Wateridge Circle
Suite 100
San Diego, CA 92121
© 2023 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY,
and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
